Valuation: Devyser Diagnostics AB

Market Cap 888M 88.69M 79.24M 73.93M 67.15M 126M 8.58B 127M 347M 4.36B 333M 326M 14.03B P/E 2026 *
87.1x
P/E 2027 * 27.3x
Enterprise Value 841M 83.99M 75.05M 70.01M 63.6M 120M 8.12B 121M 329M 4.13B 315M 308M 13.28B EV / Sales 2026 *
3.42x
EV / Sales 2027 * 2.85x
Free-Float
70.78%
Yield 2026 *
-
Yield 2027 * -
1 day-3.13%
1 week+4.75%
Current month+4.75%
1 month-12.88%
3 months-12.22%
6 months-31.33%
Current year-54.65%
1 week 4.42
Extreme 4.42
4.82
1 month 4.38
Extreme 4.385
5.35
Current year 4.38
Extreme 4.385
10.56
1 year 4.38
Extreme 4.385
12.44
3 years 4.38
Extreme 4.385
14.2
5 years 4.38
Extreme 4.385
14.2
10 years 4.38
Extreme 4.385
14.2
Manager TitleAgeSince
Chief Executive Officer 59 04/08/2025
Director of Finance/CFO 43 01/01/2021
Chief Tech/Sci/R&D Officer 48 01/02/2024
Director TitleAgeSince
Chairman 57 27/05/2021
Director/Board Member 49 01/01/2021
Director/Board Member 72 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-3.13%+4.75% - - 88.69M
+4.16%+4.16%+49.37%+94.17% 74.68B
+0.46%-0.97%+23.51%+79.34% 58.7B
+0.17%+0.35%+6.85%+34.55% 48.36B
+0.50%-2.14%+331.33%+702.20% 43.05B
-0.72%-3.99%+28.50%+29.94% 42.48B
+0.34%-0.52%+6.56%+109.35% 41.39B
-0.11%+1.96%+9.19%+52.66% 31.29B
-0.50%-3.10%-10.19%-14.35% 23.93B
-3.32%-10.86%-37.32%+316.28% 22.22B
Average -0.21%-2.18%+45.31%+156.02% 42.9B
Weighted average by Cap. +0.68%-1.56%+52.73%+149.50%

Financials

2026 *2027 *
Net sales 246M 24.55M 21.94M 20.47M 18.59M 35.01M 2.38B 35.27M 96.09M 1.21B 92.17M 90.18M 3.88B 298M 29.71M 26.54M 24.76M 22.49M 42.36M 2.87B 42.68M 116M 1.46B 112M 109M 4.7B
Net income 10.07M 1M 898K 838K 761K 1.43M 97.21M 1.44M 3.93M 49.44M 3.77M 3.69M 159M 31.97M 3.19M 2.85M 2.66M 2.42M 4.55M 309M 4.59M 12.49M 157M 11.98M 11.72M 505M
Net Debt -47.04M -4.7M -4.2M -3.91M -3.56M -6.7M -454M -6.75M -18.38M -231M -17.63M -17.25M -743M -39M -3.89M -3.48M -3.25M -2.95M -5.55M -377M -5.59M -15.24M -192M -14.62M -14.3M -616M
Projected Income Statement - Annual - Devyser Diagnostics AB
Logo Devyser Diagnostics AB
Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.
Employees
110
Date Price Change
07/10/26 €4.635 -3.13%
06/10/26 €4.785 +1.16%
05/10/26 €4.730 -1.15%
02/10/26 €4.785 +6.22%
01/10/26 €4.505 +1.81%
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Devyser Diagnostics AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
35.08DKK
Average target price
65.94DKK
Spread / Average Target
+87.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Devyser Diagnostics AB